MDPI and ACS Style
Meregalli, C.; Maricich, Y.; Cavaletti, G.; Canta, A.; Carozzi, V.A.; Chiorazzi, A.; Newbold, E.; Marmiroli, P.; Ceresa, C.; Diani, A.;
et al. Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers 2021, 13, 5013.
https://doi.org/10.3390/cancers13195013
AMA Style
Meregalli C, Maricich Y, Cavaletti G, Canta A, Carozzi VA, Chiorazzi A, Newbold E, Marmiroli P, Ceresa C, Diani A,
et al. Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers. 2021; 13(19):5013.
https://doi.org/10.3390/cancers13195013
Chicago/Turabian Style
Meregalli, Cristina, Yuri Maricich, Guido Cavaletti, Annalisa Canta, Valentina A. Carozzi, Alessia Chiorazzi, Evan Newbold, Paola Marmiroli, Cecilia Ceresa, Arthur Diani,
and et al. 2021. "Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models" Cancers 13, no. 19: 5013.
https://doi.org/10.3390/cancers13195013